-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Globus Medical, Raises Price Target to $105

Benzinga·12/17/2025 19:51:19
语音播报
Canaccord Genuity analyst Caitlin Cronin maintains Globus Medical (NYSE:GMED) with a Buy and raises the price target from $90 to $105.